Clinical trial · Observational
Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1
Prostate, Lung, Colon, and Ovarian Cancer (PLCO) Screen Trial
NCT00218179CI-TRIAL-00025584completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is the leading cause of cancer death in the United States. Currently it remains impossible to predict which smokers will get cancer. Each puff of a cigarette delivers a mixture of over 60 known carcinogens. Biomarkers that quantify carcinogen levels and metabolism are a useful tool and available to use. The purpose of this study is to assess the link between tobacco smoke carcinogen biomarkers and the risk of developing lung cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Tobacco Use Disorder | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cases
- description
- Lung cancer cases diagnosed prior to 2007 among baseline smokers in the PLCO
- interventionNames
- Other: Non-intervention
- label
- Controls
- description
- Subjects without lung cancer among smokers at baseline in the PLCO study
- interventionNames
- Other: Non-intervention
Primary outcomes (1)
- measure
- Lung cancer
- timeFrame
- Cumulative incidence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 55 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * Screening arm participants in the Prostate, Lung, Colon, and Ovarian Screen Trial (PLCO) * Reported smoking on baseline questionnaire of PLCO * Contributed biorepository samples Exclusion Criteria: * Unstable physical or mental health
References
Publications (3)
- RESULTChurch TR, Haznadar M, Geisser MS, Anderson KE, Caporaso NE, Le C, Abdullah SB, Hecht SS, Oken MM, Van Ness B. Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk. Int J Mol Epidemiol Genet. 2010 Aug 5;1(4):295-309. PMID 21532841
- RESULTChurch TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, Benoit AR, Carmella SG, Hecht SS. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):260-6. doi: 10.1158/1055-9965.EPI-08-0718. PMID 19124507
- RESULTFang G, Haznadar M, Wang W, Yu H, Steinbach M, Church TR, Oetting WS, Van Ness B, Kumar V. High-order SNP combinations associated with complex diseases: efficient discovery, statistical power and functional interactions. PLoS One. 2012;7(4):e33531. doi: 10.1371/journal.pone.0033531. Epub 2012 Apr 19. PMID 22536319